Major players in the isothermal nucleic acid amplification technology (INAAT) market are Alere, Biomeriux, Qiagen and Becton, Dickinson and Company. The global isothermal nucleic acid amplification technology (INAAT) market is expected to grow from $2.
New York, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Isothermal Nucleic Acid Amplification Technology (INAAT) Global Market Report 2021: COVID-19 Growth And Change To 2030" - https://www.reportlinker.com/p06151577/?utm_source=GNW
36 billion in 2020 to $2.62 billion in 2021 at a compound annual growth rate (CAGR) of 11%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $4.03 billion in 2025 at a CAGR of 11.4%.
The isothermal nucleic acid amplification technology (INAAT) market consists of sales of isothermal nucleic acid amplification technologies and related services.The services include only installation and maintenance services offered by equipment manufacturers.
Isothermal nucleic acid amplification technologies are used to amplify DNA sequence from two different nucleic acids segments at the constant temperature.
The isothermal nucleic acid amplification technology (INAAT) market covered in this report is segmented by product into instrument, reagent. It is also segmented by end-user into hospital, reference laboratories, others; by technology into NASBA, HAD and by application into blood screening, infectious disease diagnostics, cancer.
The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The market for isothermal nucleic acid amplification technology is strictly regulated by stringent regulatory policies that govern the functioning, approvals and standards set for the manufacturers of this market.These regulations discourage companies to invest in new products for research and development or enter new markets.
For example, the administration of US food and drugs (USFDA) requires multi-laboratory validation of a loop-mediating isothermal amplification which takes twice as much time as the Commission for European regulatory to review the process. Long regulatory procedures delay the scope for further study of the safety and efficacy of devices and affects the operating cycle of the vendors thereby adversely affecting the growth of the market.
Nanostructures are being incorporated to in vitro diagnostics and in vitro rapid diagnostic tests (RDT) in order to improve existing tests and make them more effective or create innovative diagnostic test approaches that are incorporated in point?of?care applications.Nanostructures/nanotechnology uses nanoparticles to enhance the action of the drug in treatment and nanotechnology is the design, characterization, production, and application of devices, structures and systems by controlled manipulation of size and shape at the nanometer scale.
For instance, a range of RDTs have been developed to diagnose syphilis such as AccuBioTech (Accu-Tell Rapid Syphilis Test), Alere, Inc. (Alere Determine), Alere/Standard Diagnostics (SD Syphilis 3.0), The Tulip Group/Qualpro (Syphicheck - WB), Cypress Diagnostics (Syphilis Rapid Test), and Omega Diagnostics (Visitect Syphilis). These RDTs allow patients to be diagnosed at the point-of-care (POC).
In 2018, Tecan, a laboratory instruments and solutions provider acquired Nugen Technologies for $54.5 million. The acquisition helps Tecan expand into new market segment of next-generation sequencing (NGS) reagents. Nugen Technologies is a biotech company founded in the year 2000. The U.S. based company having its headquarters in California, manufactures molecular biology reagents for next-generation sequencing genomic analysis.
The incidence of infectious diseases such as H. influenzae, S. pneumonia (respiratory tract infections), N. gonorrhoeae, C. trachomatis (genital infections), and TB are increasing and require isothermal nucleic acid amplification technology (INAAT) to diagnose them. For instance, according to World Health Organization 17 million people lose their lives to infectious diseases every year. Another report by Centers for Disease Control show that number of diseases from mosquitoes, ticks and fleas like West Nile, Zika, Malaria and Lyme disease increased three times. Similarly, as per a survey done by NCBI, around 50% of the population in the United States (approx. 157 million) was suffering from at least one chronic disease in 2020. Increase in infectious or chronic disease drives the demand for diagnosing through isothermal nucleic acid amplification technology.
The isothermal nucleic acid amplification technology market is regulated by government agencies such as European Medicines Agency (EMA), USFDA (the US food and drug ministration), and others.For instance, according to USFDA, each medical device is classified into three groups which is class 1, class 2 & class 3.
Class 1 devices require less regulatory control and class 3 requires the most.However, devices which are not been marketed before as in the case of INAAT devices, will fall under class 3 devices as per the medical device amendment.
Such devices require approval of a Pre-Market Application (PMA) under the federal law. Premarket approval (PMA) is the scientific and regulatory review process of the FDA to assess the safety and efficacy of medical devices of Class 3.
The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Read the full report: https://www.reportlinker.com/p06151577/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001